Sylke Maas - BioNTech Vice Strategy
| BNTX Stock | USD 118.39 2.33 1.93% |
Executive
Sylke Maas is Vice Strategy of BioNTech SE
| Address | An der Goldgrube 12, Mainz, Germany, 55131 |
| Phone | 49 6131 9084 0 |
| Web | https://www.biontech.de |
BioNTech Management Efficiency
The company has return on total asset (ROA) of (0.0124) % which means that it has lost $0.0124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.024) %, meaning that it created substantial loss on money invested by shareholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, BioNTech's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.07 in 2024, whereas Return On Capital Employed is likely to drop 0.03 in 2024. At this time, BioNTech's Fixed Asset Turnover is fairly stable compared to the past year. Return On Assets is likely to rise to 0.07 in 2024, whereas Debt To Assets are likely to drop 0.01 in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Erika Trahan | Novavax | N/A | |
| Elaine OHara | Novavax | 56 | |
| Christine Wilson | Krystal Biotech | N/A | |
| John Thomas | Krystal Biotech | N/A | |
| Christine Utter | PTC Therapeutics | 46 | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
| Julianne MBA | Crispr Therapeutics AG | N/A | |
| Joaquim Marques | Ginkgo Bioworks Holdings | N/A | |
| JD Esq | Novavax | 53 | |
| Susan Kim | Crispr Therapeutics AG | N/A | |
| Hege SollieZetlmayer | PTC Therapeutics | N/A | |
| Emily Hill | PTC Therapeutics | 44 | |
| Ram Kamineni | Krystal Biotech | N/A | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| MD MBA | Ocean Biomedical | 59 | |
| Mark Underwood | Madrigal Pharmaceuticals | N/A | |
| Robert MD | Novavax | N/A | |
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Stephen Kennedy | Crispr Therapeutics AG | N/A | |
| Jennifer McDonough | Krystal Biotech | N/A | |
Management Performance
| Return On Equity | -0.024 | ||||
| Return On Asset | -0.0124 |
BioNTech SE Leadership Team
Elected by the shareholders, the BioNTech's board of directors comprises two types of representatives: BioNTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioNTech. The board's role is to monitor BioNTech's management team and ensure that shareholders' interests are well served. BioNTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioNTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Katalin Kariko, Senior Therapies | ||
| Jens Holstein, CFO Board | ||
| Sylke Maas, Vice Strategy | ||
| Michael Boehler, MD Communications | ||
| Siegbert Kloos, Datand Digital | ||
| Sierk Poetting, COO MD | ||
| Pr MD, CoFounder Board | ||
| Zach Taylor, Senior Strategy | ||
| Ozlem MD, Chief CoFounder | ||
| Sean Marett, Executive Officer | ||
| Oliver Henning, Senior Operations | ||
| Oliver Hennig, Senior Operations | ||
| Ugur MD, CEO CoFounder | ||
| Lisa Birringer, Senior Accounting | ||
| James Ryan, Chief Board | ||
| Ryan Richardson, MD Officer | ||
| Sebastian MD, Senior Research |
BioNTech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioNTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.024 | ||||
| Return On Asset | -0.0124 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 10.99 B | ||||
| Shares Outstanding | 239.74 M | ||||
| Shares Owned By Insiders | 61.65 % | ||||
| Shares Owned By Institutions | 20.64 % | ||||
| Number Of Shares Shorted | 2.47 M | ||||
| Price To Earning | 5.19 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.